Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation - 31/01/18
, Hang Zhu, MD a, Yundai Chen, MD, PhD a, Gregory Y.H. Lip, MD b, c, * Abstract |
Background |
There is uncertainty whether a focus on modifiable bleeding risk factors offers better prediction of major bleeding than other existing bleeding risk scores.
Methods |
This study compared a score based on numbers of the modifiable bleeding risk factors recommended in the 2016 European guidelines (“European risk score”) versus other published bleeding risk scores that have been derived and validated in atrial fibrillation subjects (HEMORR2HAGES, HAS-BLED, ATRIA, and ORBIT) in a large hospital-based cohort of Chinese inpatients with atrial fibrillation.
Results |
The European score had modest predictive ability for major bleeding (c-index 0.63, 95% confidence interval 0.56-0.69) and intracranial hemorrhage (0.72, 0.65-0.79) but nonsignificantly (and poorly) predicted extracranial bleeding (0.55, 0.54-0.56; P = .361). The HAS-BLED score was superior to predict bleeding events compared with the European score, with the differences between c-indexes of 0.10-0.12 (Delong test, all P < .05), net reclassification improvement values of 13.0%-34.5% (all P < .05), and integrated discrimination improvement values of 0.7%-1.4% (all P < .05). The European score had similar predictive value to other bleeding risk schemes (HEMORR2HAGES, ATRIA, and ORBIT) for major bleeding and intracranial hemorrhage (all P > .05). Decision curve analysis clearly shows that HAS-BLED had better net benefit of predicting major bleeding compared with the European score.
Conclusions |
Relying on bleeding risk assessment using modifiable bleeding risk factors alone is an inferior strategy for predicting atrial fibrillation patients for major bleeding. Our observations reaffirm the Asian guideline recommendations with HAS-BLED for bleeding risk assessment in patients with atrial fibrillation.
Le texte complet de cet article est disponible en PDF.Keywords : Atrial fibrillation, Bleeding, HAS-BLED, Risk factors, Risk stratification
Plan
| Funding: This study was supported by the Chinese PLA Healthcare Foundation (13BJZ40), Beijing Natural Science Foundation (7142149), and National Natural Science Foundation of China (H2501). |
|
| Conflict of Interest: GYHL has been a consultant for Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo; and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo. |
|
| Authorship: YG and GYHL are guarantors of the manuscript and contributed to the original idea, data analyses, and manuscript drafting and revisions. HZ and YC contributed to the manuscript drafting and revisions. All of the authors reviewed and approved the final manuscript. |
Vol 131 - N° 2
P. 185-192 - février 2018 Retour au numéro
Article précédent
- Efficacy of a Transition Clinic on Hospital Readmissions
- Vidya Chakravarthy, Mary J. Ryan, Amir Jaffer, Robyn Golden, Regina McClenton, Jisu Kim, Irwin Press, Tricia J. Johnson
- Reducing Inappropriate Testing for the Evaluation of Diarrhea Among Hospitalized Patients
- Chad E. Tewell, Thomas R. Talbot, George E. Nelson, Bryan D. Harris, Whitney A. Jones, Narinder M. Midha, David P. Mulherin, Eric B. Stephens, Anuj Thirwani, Patty W. Wright
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?